Why is Humana (HUM) stock up today?

Humana shares are up about 0.21% to $407.00 today, holding near the top of a narrow day range, as a cluster of analyst actions over the past 24–48 hours renewed Wall Street attention on the managed-care company. Wells Fargo upgraded Humana, a move that sent shares rising on July 13, and three separate firms — Truist, TD Cowen, and Mizuho — all raised their price targets on the stock, signaling that analysts see more value in Humana after a period of pressure on its Medicare Advantage (MA) business.

The analyst actions came alongside fresh coverage of Humana's core business challenge: whether it can achieve a 3% profit margin in its Medicare Advantage segment. Medicare Advantage is a government-funded alternative to traditional Medicare where insurers like Humana manage care for seniors in exchange for per-member monthly payments. Analysts at Mizuho maintained an Outperform rating and raised their target to $468 from $390, while Truist raised its target to $415 from $320 but kept a Hold rating, and TD Cowen lifted its target to $350 from $211 while also maintaining a Hold. The divergence between targets and ratings reflects ongoing uncertainty about Humana's path back to profitability in MA.

The broader healthcare sector also provided a tailwind, with healthcare stocks advancing late in the session on July 13, as tracked by peer moves in XLV (the healthcare sector ETF). The S&P 500 is up 0.17% and the tech-heavy QQQ is up 0.96% today, suggesting a modestly risk-on backdrop. Macro data released this morning — including CPI figures — and Fed Chairman Warsh's congressional testimony are the main market-level events of the day, though no direct link to Humana's move is stated in the available data.

Humana last reported Q1 earnings per share of $10.31, slightly above the $10.20 estimate, on revenue of $39.65 billion, with revenue growing 23.5% year-over-year even as earnings declined 4.6%. The stock carries a trailing P/E (price-to-earnings ratio) of 43.3 and a forward P/E of 25.7, reflecting expectations for earnings improvement ahead. The next scheduled earnings report is July 29, which will be watched closely for any update on the Medicare Advantage margin recovery story.